Key result
Cardiovascular prevention centers on standard pharmacotherapy and lifestyle, reserving novel add-on therapies for high-risk patients.
Answers are grounded in this paper and cite their sources.
Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide. For many years guidelines have listed optimal preventive therapy. More recently, novel therapeutic options have broadened the options for state-of-the-art CV risk management (CVRM). In the majority of patients with CVD, risk lowering can be achieved by utilising standard preventive medication combined with lifestyle modifications. In a minority of patients, add-on therapies should be considered to further reduce the large residual CV risk. However, the choice of which drug combination to prescribe and in which patients has become increasingly complicated, and is dependent on both the absolute CV risk and the reason for the high risk. In this review, we discuss therapeutic decisions in CVRM, focusing on (1) the absolute CV risk of the patient and (2) the pros and cons of novel treatment options.
No takes yet. Share an insight, caveat, or question.
Hoogeveen et al. (2021) conducted a review in Cardiovascular disease. Novel add-on therapies in cardiovascular risk management vs. Standard preventive medication and lifestyle modifications was evaluated. Cardiovascular risk management relies on standard preventive drugs and lifestyle changes for most patients, while novel add-on therapies are guided by absolute risk and underlying risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: